TFX Stock Analysis: Teleflex | NYSE

Vascular Access, Hemostatic Devices, Interventional Catheters, Surgical Instruments

Total Rating 40

Safety 85

Buy Signal 0.10

Medical Instruments & Supplies
Industry Rotation: +4.2

Market Cap: 5.31B
Avg Turnover: 107M

Risk 3d forecast

Volatility33.8%

VaR 5^th Pctl5.05%

VaR vs Median-7.47%

Reward TTM

Sharpe Ratio0.13

Rel. Str. IBD43.6

Rel. Str. Peer Group49.4

Character TTM

Beta0.612

Beta Downside0.919

Hurst Exponent0.574

Drawdowns 3y

Max DD60.15%

CAGR/Max DD-0.20

CAGR/Mean DD-0.36

EPS (Earnings per Share)

EPS CAGR: -9.90%
EPS Trend: -65.3%

Last SUE: 0.69
Qual. Beats: 0

Revenue

Rev. CAGR: -2.38%
Rev. Trend: -43.1%

Last SUE: 0.02
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 11.7 years of data

Jan -1.8% 11

Feb +1.4% 17

Mar +1.3% 11

Apr -1.3% 8

May -0.4% 5

Jun -0.9% 8

Jul +0.3% 13

Aug -0.1% 5

Sep -5.2% 31

Oct -6.0% 41

Nov +4.4% 12

Dec +5.7% 35

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TFX Teleflex

Teleflex Incorporated (NYSE: TFX) is a U.S.-based medical device company that designs, develops, manufactures, and supplies single-use medical devices used in critical care, surgical, and interventional procedures. Founded in 1943 and headquartered in Wayne, Pennsylvania, the company operates globally across the United States, Europe, the Middle East, Africa, and the Asia Pacific.

The company organizes its products into several core categories: vascular and emergency medicine products (including Arrow branded catheters, EZ-IO intraosseous access systems, and QuikClot hemostatic products), interventional products (such as GuideLiner and Turnpike catheters, MANTA vascular closure devices, and drug-coated balloons), and surgical products (including Weck and MiniLap instruments, fascial closure systems, and powered bariatric staplers). Teleflex serves hospitals, healthcare providers, and medical device manufacturers, and also sells products online.

As a player in the Health Care Equipment sub-industry, Teleflex operates a diversified medical device business model centered on single-use disposable products, which typically generate recurring revenue streams tied to procedure volumes rather than durable capital equipment sales. Its broad portfolio of established brands across multiple clinical specialties helps reduce dependence on any single product line.

Headlines to Watch Out For

MANTA closure device expands interventional segment market share
Hospital capital spending constraints pressure surgical product revenue
Debt paydown limits acquisition and share repurchase capacity

Piotroski VR-10 (Strict) 3.0

Net Income: -1.03b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.38 > 1.0
NWC/Revenue: 44.43% < 20% (prev 33.13%; Δ 11.30% < -1%)
CFO/TA 0.06 > 3% & CFO 402.4m > Net Income -1.03b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.60 > 1.5 & < 3
Outstanding Shares: last quarter (43.7m) vs 12m ago -4.93% < -2%
Gross Margin: 53.77% > 18% (prev 55.59%; Δ -1.82% > 0.5%)
Asset Turnover: 36.73% > 50% (prev 41.24%; Δ -4.51% > 0%)
Interest Coverage Ratio: -2.57 > 6 (EBIT TTM -306.7m / Interest Expense TTM 119.4m)

Altman Z'' 3.15

A: 0.17 (Total Current Assets 1.88b - Total Current Liabilities 720.4m) / Total Assets 6.79b
B: 0.47 (Retained Earnings 3.21b / Total Assets 6.79b)
C: -0.04 (EBIT TTM -306.7m / Avg Total Assets 7.08b)
D: 0.75 (Book Value of Equity 2.90b / Total Liabilities 3.88b)
Altman-Z'' = 3.15 = A

Beneish M -3.29

DSRI: 0.83 (Receivables 364.6m/513.8m, Revenue 2.60b/3.04b)
GMI: 1.03 (GM 55.59% / 53.77%)
AQI: 0.95 (AQ_t 0.64 / AQ_t-1 0.68)
SGI: 0.86 (Revenue 2.60b / 3.04b)
TATA: -0.21 (NI -1.03b - CFO 402.4m) / TA 6.79b)
Beneish M = -3.29 (Cap -4..+1) = AA

What is the price of TFX shares?

As of October 10, 2026, the stock is trading at USD 125.12 with a total of 424,645 shares traded. Over the past week, the price has changed by +0.81%, over one month by -7.81%, over three months by -6.42% and over the past year by +1.45%.

Current recommended Stop Loss: 115.90 (which is 7.4% or 2.5 ATR below the current price).

Is TFX a buy, sell or hold?

Teleflex has received a consensus analysts rating of 3.62. Therefore, it is recommended to hold TFX.

StrongBuy: 2
Buy: 4
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TFX price?

Analysts Target Price	154.7	23.7%

Teleflex (TFX) - Fundamental Data Overview as of 07 October 2026

Market Cap USD = 5.31b (5.31b USD * 1.0 USD.USD)
P/E Forward = 11.0132
P/S = 2.3538
P/B = 1.8221
P/EG = 0.1641
Revenue TTM = 2.60b USD
EBIT TTM = -306.7m USD
EBITDA TTM = -158.5m USD
Long Term Debt = 2.72b USD (from longTermDebt, last quarter)
Short Term Debt = 87.5m USD (from shortTermDebt, last quarter)
Debt = 2.94b USD (from shortLongTermDebtTotal, last quarter) + Leases 64.5m
Net Debt = 2.64b USD (calculated: Debt 2.94b - CCE 300.2m)
Enterprise Value = 7.94b USD (5.31b + Debt 2.94b - CCE 300.2m)
Interest Coverage Ratio = -2.57 (Ebit TTM -306.7m / Interest Expense TTM 119.4m)
EV/FCF = 20.34x (Enterprise Value 7.94b / FCF TTM 390.6m)
FCF Yield = 4.92% (FCF TTM 390.6m / Enterprise Value 7.94b)
FCF Margin = 15.02% (FCF TTM 390.6m / Revenue TTM 2.60b)
Net Margin = -39.58% (Net Income TTM -1.03b / Revenue TTM 2.60b)
Gross Margin = 53.77% ((Revenue TTM 2.60b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Gross Margin QoQ = 58.16% (prev 56.07%)
Tobins Q-Ratio = 1.17 (Enterprise Value 7.94b / Total Assets 6.79b)
Interest Expense / Debt = 4.07% (Interest Expense 119.4m / Debt 2.94b)
Taxrate = 7.48% (3.38m / 45.1m)
NOPAT = -283.8m (EBIT -306.7m * (1 - 7.48%)) [loss with tax shield]
Current Ratio = 2.60 (Total Current Assets 1.88b / Total Current Liabilities 720.4m)
Debt / Equity = 1.01 (Debt 2.94b / totalStockholderEquity, last quarter 2.90b)
Debt / EBITDA = -16.64 (negative EBITDA) (Net Debt 2.64b / EBITDA -158.5m)
Debt / FCF = 6.75 (Net Debt 2.64b / FCF TTM 390.6m)
Total Stockholder Equity = 3.23b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.54% (Net Income -1.03b / Total Assets 6.79b)
RoE = -31.83% (Net Income TTM -1.03b / Total Stockholder Equity 3.23b)
RoCE = -5.15% (EBIT -306.7m / Capital Employed (Equity 3.23b + L.T.Debt 2.72b))
RoIC = -4.71% (negative operating profit) (NOPAT -283.8m / Invested Capital 6.02b)
WACC = 6.58% (E(5.31b)/V(8.24b) * Re(8.14%) + D(2.94b)/V(8.24b) * Rd(4.07%) * (1-Tc(0.07)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.06 | Cagr: -3.58%
[DCF] Terminal Value 75.24% ; FCFF base≈393.0m ; Y1≈389.8m ; Y5≈402.8m
[DCF] Fair Price = 86.03 (EV 6.28b - Net Debt 2.64b = Equity 3.65b / Shares 42.4m; r=8.35% [WACC [floored]]; 5y FCF grow -1.47% → 2.50% )
EPS Correlation: -65.28 | EPS CAGR: -9.90% | SUE: 0.69 | # QB: 0
Revenue Correlation: -43.11 | Revenue CAGR: -2.38% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.89 | Chg30d=-0.04% | Revisions=+77% | Analysts=12
EPS current Year (2026-12-31): EPS=7.08 | Chg30d=-0.01% | Revisions=+77% | GrowthEPS=+1.4% | GrowthRev=+14.3%
EPS next Year (2027-12-31): EPS=10.95 | Chg30d=-0.03% | Revisions=+53% | GrowthEPS=+54.7% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +80% (up=30, down=2)